Suven Life Sciences has received approval to incorporate a wholly owned subsidiary (WOS) namely ‘Suven Neurosciences’ in Singapore. The new entity will be the Clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for treatment of neurological and other disorders.
The board of directors of the company, at its meeting held on July 08, 2026, has inter-alia considered and approved the same.
Suven Life Sciences provides wide range of Drug Discovery and Development Support Services (DDDSS) to global Pharma and Biotech companies. Suven has state-of-art facilities with highly qualified & experienced team of scientists.
